METHYLPHENIDATE HYDROCHLORIDE | A210354 | ASCENT PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Rising Pharma Holdings, Inc. FDA-2025-P-5439 · 9 docket documents Rising Pharma Holdings, Inc. filed this suitability petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act and 21 CFR Section 314.93, requesting FDA approval to submit an ANDA for Methylphenidate Hydrochloride Chewable Tablets, 20 mg, a strength that differs from the current | Suitability | 2025-10-17 | Granted | Rising Pharma Holdings, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$3.06
per ea
Lowest NADAC/Unit
$1.30
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 31722092801METHYLPHENIDATE 10 MG CHEW TAB | $3.06 | EA | Generic | — | 2026-06-17 |
| 31722092701METHYLPHENIDATE 5 MG CHEW TAB | $1.86 | EA | Generic | — | 2026-06-17 |
| 31722092601METHYLPHENIDATE 2.5 MG CHEW TB | $1.30 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.